Your search for Patient-reported outcomes returned 6 results.

Addressing the Restricted Use of DAA therapies

Results of a new US cost effectiveness study indicate that effective direct acting antiviral (DAA) therapies should be not be restricted to only those HCV-infected patients with advanced fibrosis. Authors note that as a society, we have an opportunity to eliminate hepatitis C by taking appropriate and timely steps, and we should be willing to pay for the current HCV ...

Read More

Coffee Decreases HCV Advanced Fibrosis Risk

New study indicates that an average daily intake of an estimated 100 mg of caffeine from coffee, tea, or soda is associated with an approximately one-third reduction in odds of advanced fibrosis, although higher intake does not seem to confer any additional benefit. Interestingly, tea intake in those who do not consume coffee may also be associated with a decrea...

Read More

Barriers to Accessing HCV Therapies in the US

Recent study indicates that newly available, interferon-free HCV therapies will significantly increase access to care for HCV infected individuals in the US, as unlike standard interferon-based therapies, interferon-free therapies are associated with minimal contraindications. However, a large proportion of US individuals with chronic hepatitis C infection ...

Read More

Real-world evaluation of eligibility for HCV therapy

In clinical practices in Italy, between January 2009 and February 2010, only 61% of patients with chronic hepatitis C were considered eligible for peginterferon/ribavirin. Reasons treatment was not indicated included patient’s age or mild disease stage. Italian Hepatologists may consider an IFN-based antiviral treatment not cost-effective in older patients ...

Read More

Outcomes improved during Hepatitis C treatment

An interferon-free and ribavirin-free anti-HCV regimen is shown to improve patient-reported outcomes during treatment Chronic HCV infection causes a tremendous clinical and economic burden to society. Patient-reported outcomes (PROs) such as health-related quality of life (HRQL) and work productivity are negatively impacted by HCV-related liver disease (cirrhosis, ...

Read More

Patient-reported HCV treatment adherence

Patient-reported factors that negatively impact adherence to HCV therapies need to be understood and addressed HCV treatment adherence is critical for patients to attain a sustained virological response (SVR), or cure. Unfortunately, up to 50% of patients have difficulty maintaining 80% adherence to HCV therapies, thereby compromising treatment outcomes. While new ...

Read More